NAD+ precursor — converts to NAD+ via the salvage pathway.
Typical dose range: 250–1000 mg
Frequency: Daily (mornings)
Route: Oral / sublingual
Half-life: Short (rapidly metabolised)
Evidence level: Limited (early clinical)
Cheaper and more practical than IV NAD+. Real benefits in healthy adults remain modest in human trials so far.